2 research outputs found
Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy
<div><p></p><p><b>Background.</b> Concurrent chemoradiotherapy cures most patients with anal squamous cell carcinoma at the cost of significant treatment-related toxicities. Intensity-modulated radiotherapy (IMRT) reduces side effects compared to older techniques, but whether proton beam therapy (PBT) offers additional advantages is unclear.</p><p><b>Material and methods.</b> Eight patients treated with PBT for anal cancer were chosen for this study. We conducted detailed plan comparisons between pencil-beam scanning PBT via two posterior oblique fields and seven-field IMRT. Cumulative dose-volume histograms were analyzed by Wilcoxon signed-rank test, and plan delivery robustness was assessed via verification computed tomography (CT) scans obtained during treatment.</p><p><b>Results.</b> Compared to IMRT, PBT reduced low dose radiation (≤ 30 Gy) to the small bowel, total pelvic bone marrow, external genitalia, femoral heads, and bladder (all p < 0.05) without compromising target coverage. For PBT versus IMRT, mean small bowel volume receiving ≥ 15 Gy (V<sub>15</sub>) was 81 versus 151 cm<sup>3</sup>, mean external genitalia V<sub>20</sub> was 14 versus 40%, and mean total pelvic bone marrow V<sub>15</sub> was 66 versus 83% (all p = 0.008). The lumbosacral bone marrow dose was higher with PBT due to beam geometry. PBT was delivered with ≤ 1.3% interfraction deviation in the dose received by 98% of the clinical target volumes.</p><p><b>Conclusion.</b> Pencil-beam scanning PBT is clinically feasible and can be robustly delivered for anal cancer patients. Compared with IMRT, PBT reduces low dose radiation to important organs at risk in this population. While the clinical benefit of these differences remains to be shown, existing data suggest that limiting low dose to the small bowel and pelvic bone marrow may reduce treatment toxicity.</p></div
Screening for Depression, Sleep-Related Disturbances, and Anxiety in Patients with Adenocarcinoma of the Pancreas: A Preliminary Study
Purpose. Screening for depression, sleep-related disturbances, and anxiety in patients with diagnosed adenocarcinoma of the
pancreas. Materials and Methods. Patients were evaluated at initial consultation and subsequent visits at the multidisciplinary
pancreatic cancer clinic at our University Cancer Center. Cross-sectional and longitudinal psychosocial distress was assessed
utilizing Personal Health Questionnaire 9 (PHQ9) to screen for depression and monitor symptoms, the Penn State Worry
Questionnaire (PSWQ) for generalized anxiety, and the University of Michigan Sleep Questionnaire to monitor sleep symptoms.
Results. Twenty-two patients diagnosed with pancreatic cancer participated during the 6-month pilot study with longitudinal
followup for thirteen patients. In this study, mild-to-moderate depressive symptoms, anxiety, and potential sleep problems were
common. Themain finding of the study was 23% of the patients who were part of this pilot project screened positive for moderately
severe major depressive symptoms, likely anxiety disorder or a potential sleep disorder during the study. One patient screened
positive formoderately severe depressive symptoms in longitudinal followup. Conclusions. Depression, anxiety, and sleep problems
are evident in patients with pancreatic cancer. Prospective, longitudinal studies, with larger groups of patients, are needed to
determine if these comorbid symptoms impact outcome and clinical course